Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 4/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NPY1R | P25929 | 1/20 | 0.31 |
| ▸ | NPY2R | P49146 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8516382 | 0.83 | — | — | |
| SCHEMBL10765099 | 0.74 | — | — | |
| SCHEMBL19710210 | 0.74 | — | — | |
| SCHEMBL1800447 | 0.74 | — | — | |
| SCHEMBL18556771 | 0.71 | SMYD3 (0.37) | SMN1; SMN2LMNAMAPTGAAKDM4E | |
| SCHEMBL10846920 | 0.71 | LMNA (0.41) | SMN1; SMN2CRBNLMNARAB9AMAPT | |
| SCHEMBL3644791 | 0.71 | SMN1; SMN2 (0.36) | SMN1; SMN2LMNAMAPTGAAKDM4E | |
| SCHEMBL11016724 | 0.70 | — | — | |
| SCHEMBL8589332 | 0.69 | — | — | |
| SCHEMBL5679235 | 0.67 | ALDH1A1 (0.41) | SMN1; SMN2LMNAMAPTGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041661-A1 | CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD | LG LIFE SCIENCES LTD. (KR) | 2010-02-18 | — | — | US | disclosed |
| CN-101558045-A | Caspase inhibitors based on pyridazinone scaffold | LG LIFE SCIENCES LTD (KR) | 2009-10-14 | — | — | CN | disclosed |
| EP-2079710-A1 | CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD | LG Life Sciences Ltd. (KR) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008056897-A1 | CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD | LG LIFE SCIENCES LTD. (KR) | 2008-05-15 | — | — | WO | disclosed |
| US-4056617-A | Organic pyridazyl phosphorothioates and their use as insecticides | SANKYO COMPANY LIMITED (JA) | 1977-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041661-A1 | CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD | CASP1, CASP2, CASP5 | SMN1; SMN2 2357/4885CRBN 933/4885LMNA 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.